Enantioselective binding of carvedilol to human serum albumin and alpha‐1‐acid glycoprotein

Abstract

AbstractCarvedilol, a highly protein‐bound beta‐blocker, is used in therapy as a racemic mixture of its two enantiomers that exhibit different pharmacological activity. The aim of this study was to evaluate the stereoselective nature of its binding to the two major plasma proteins: albumin and alpha‐1‐acid glycoprotein. The determination of the plasma protein‐binding degree for carvedilol and its enantiomers was achieved using ultrafiltration for the separation of the free fraction, followed by LC‐MS/MS quantification, using two different developed and validated methods in terms of stationary phase: achiral C18 type and chiral ovomucoid type. Furthermore, molecular docking methods were applied in order to investigate and to better understand the mechanism of protein‐binding for S‐(−)‐ and R‐(+)‐carvedilol. A difference in the binding behavior of the two enantiomers to the plasma proteins was observed when taken individually, with R‐(+)‐carvedilol having a higher affinity for albumin and S‐(−)‐carvedilol for alpha‐1‐acid glycoprotein. However, in the case of the racemic mixture, the binding of the S enantiomer to alpha‐1‐acid glycoprotein seemed to be influenced by the presence of its antipode, although no such influence was observed in the case of albumin. The results raise the question of a binding competition between the two enantiomers for alpha‐1‐acid glycoprotein.